跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
212Pb-PSMA
首页
药物
212Pb-PSMA
212Pb-PSMA
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Lead and thorium compounds
US 10377778 B2
申请人: SCIENCONS AS
优先权: 2017
CN
US
WO
11 件公开
PSMA-TARGETING RADIOACTIVE METAL COMPLEX CONTAINING NITRO AROMATIC HETEROCYCLIC GROUP AND PREPARATION THEREOF
WO 2023231452 A1
申请人: UNIV BEIJING NORMAL
优先权: 2023
CN
WO
2 件公开
COMPOUND FOR DUAL TARGETING OF TUMOR CELL, AND PREPARATION METHOD THEREFOR AND USE THEREOF
WO 2025151982 A1
申请人: PEKING UNION MEDICAL COLLEGE HOSPITAL CAMS
优先权: 2024
CN
WO
2 件公开
Labeled inhibitors of prostate-specific membrane antigen (PSMA), their use as imaging agents and agents for treatment of PSMA-expressing cancers
CN 121534209 A
申请人: UNIV HEIDELBERG
优先权: 2018
CN
Application of 212Pb-EB-PSMA-617 in prostate cancer
CN 117180460 A
申请人: BEIJING SINOTAU PHARMACEUTICALS CO LTD
优先权: 2023
CN
药物
反馈